Integra Lifesciences Holdings (IART) Total Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings has reported Total Current Liabilities for 18 years, with the latest figure at $330.9 million in Q2 2026.

• Quarterly Total Current Liabilities fell 64.41% year-over-year to $330.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $330.9 million (down 64.41% YoY) and the FY2025 annual result came in at $456.0 million, down 50.55% from the prior year.
• Total Current Liabilities eased to $330.9 million in Q2 2026 per IART's latest filing, from $346.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $929.8 million in Q2 2025 and troughed at $282.3 million in Q1 2023.
• A 5-year average of $465.0 million and a median of $338.9 million in 2026 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities surged 203.73% in 2025, then sank 64.41% in 2026.
• Over 5 years, Total Current Liabilities stood at $320.9 million in 2022, then declined by 4.34% to $307.0 million in 2023, then surged by 200.39% to $922.1 million in 2024, then sank by 50.55% to $456.0 million in 2025, then retreated by 27.44% to $330.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $330.9 million, $346.8 million, and $456.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.